BC Innovations | Dec 22, 2016
Finance

Starting up stem cells

In launching BlueRock Therapeutics with a $225 million series A round, comprehensive IP portfolio and set of strategic partnerships, Versant Ventures and Bayer AG are sending a message they are not only ready to go...
BC Week In Review | Jul 11, 2016
Clinical News

C-Cure: Phase III data

Top-line data from the double-blind, European and Israeli Phase III CHART-1 trial in 271 evaluable patients with advanced, symptomatic CHF showed that a catheter injection of C-Cure missed the primary endpoint of improving a composite...
BioCentury | Jul 11, 2016
Finance

Shedding red

Steve Edelson, Senior Editor   Brexit nearly wiped out what looked to be a rebound quarter for biotech. Only two market cap segments finished in positive territory, and smaller companies continued to get pounded. Big...
BC Extra | Jun 29, 2016
Clinical News

Celyad slides on Phase III heart failure miss

Celyad S.A. (Euronext:CYAD; NASDAQ:CYAD) said cell therapy C-Cure missed the primary endpoint in the Phase III CHART-1 study to treat ischemic heart failure. The company sank EUR 15.95 (40%) to EUR 23.52 in Europe and...
BioCentury | Apr 4, 2016
Finance

2Q milestones

2Q milestones Company Product Indication Event Milestone Ablynx N.V. (Euronext:ABLX) ALX-0171 Respiratory syncytial virus (RSV) infection Ph I/IIa data 2Q16 Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) Nuplazid pimavanserin Parkinson's disease psychosis (PDP) PDUFA date 5/1/16 Acucela Inc....
BioCentury | Jan 11, 2016
Finance

Sowing season

Stephen Hansen, Associate Editor   BUYSIDE VIEW XXIV While the biotech sector's three-year rocket ride isn't likely to continue in 2016, fund managers are still anticipating a slew of high-profile milestones in the New Year....
BC Week In Review | Sep 28, 2015
Company News

Celyad, Medisun International deal

Celyad granted Medisun rights to commercialize C-Cure in Taiwan and China, including Hong Kong and Macau. Under the 15-year deal, Celyad is eligible for royalties of 10-30% on revenues and for profit sharing on 20-25%...
BioCentury | Jul 20, 2015
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 7/17 cls Celgene Corp. (NASDAQ:CELG) BMO Capital Markets Jim Birchenough Price target Outperform 13% $134.52 Deutsche Bank Robyn Karnauskas Price...
BC Extra | Jun 20, 2015
Financial News

Celyad shares fall after U.S. listing

Celyad S.A. (NASDAQ:CYAD; Euronext:CYAD) dropped $13.99 (20%) to $54.57 in its first day of trading on NASDAQ Friday after it raised $100.1 million through the sale of ADSs and a private placement of ordinary shares....
BC Week In Review | Apr 13, 2015
Clinical News

C-Cure: Phase III ongoing

An independent DSMB recommended continuation of the double-blind, sham-controlled, European and Israeli Phase III CHART-1 trial evaluating a catheter injection of C-Cure based on a review of safety and efficacy data after all 240 advanced...
Items per page:
1 - 10 of 33